Oncolytic Viruses for Systemic Administration: Engineering a Whole Different Animal

Atasheva, Svetlana; Shayakhmetov, Dmitry M.

doi:10.1016/j.ymthe.2021.02.001

Cited by 9 publications

(8 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[91,92] Second, viruses are easily neutralized by complement-and immunoglobulin M (IgM)-dependent antiviral mechanisms, leading to their sequestration in liver Kupffer cells and splenic macrophages. [93][94][95] As natural IgM binds to the virus, a complement cascade is activated and the virus is rapidly inactivated. By interacting with scavenger, Fc, and complement receptors on immune cells, IgM and complement facilitate rapid sequestration of the virus.…”

Section: Systemic Deliverymentioning

confidence: 99%

Oncolytic Virus‐Driven Biotherapies from Bench to Bedside

Duan

Wang

Qiao

et al. 2023

Small

View full text Add to dashboard Cite

With advances in cancer biology and an ever‐deepening understanding of molecular virology, oncolytic virus (OV)‐driven therapies have developed rapidly and become a promising alternative to traditional cancer therapies. In recent years, satisfactory results for oncolytic virus therapy (OVT) are achieved at both the cellular and organismal levels, and efforts are being increasingly directed toward clinical trials. Unfortunately, OVT remains ineffective in these trials, especially when performed using only a single OV reagent. In contrast, integrated approaches, such as using immunotherapy, chemotherapy, or radiotherapy, alongside OVT have demonstrated considerable efficacy. The challenges of OVT in clinical efficacy include the restricted scope of intratumoral injections and poor targeting of intravenous administration. Further optimization of OVT delivery is needed before OVs become a viable therapy for tumor treatment. In this review, the development process and antitumor mechanisms of OVs are introduced. The advances in OVT delivery routes to provide perspectives and directions for the improvement of OVT delivery are highlighted. This review also discusses the advantages and limitations of OVT monotherapy and combination therapy through the lens of recent clinical trials and aims to chart a course toward safer and more effective OVT strategies.

show abstract

Section: Systemic Deliverymentioning

confidence: 99%

Oncolytic Virus‐Driven Biotherapies from Bench to Bedside

Duan

Wang

Qiao

et al. 2023

Small

View full text Add to dashboard Cite

show abstract

“…These "armed" OVs with immunostimulatory or anti-cancer transgenes can be used as monotherapy or in combination with other therapeutic modalities to reduce side effects and improve anti-tumor efficacy. If an "armed" OV is designed for systemic delivery, it could be one of the options for treating patients with metastatic tumors (68). Currently, the primary use is to genetically engineer oncolytic viruses to carry PD-1/PD-L1 antibody genes or otherwise "armed" them to enhance the sensitivity of tumor cells to ICIs.…”

Section: "Armed" Recombinant Oncolytic Viruses Enhance the Efficacy O...mentioning

confidence: 99%

Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option

et al. 2022

View full text Add to dashboard Cite

Immunotherapy is one of the promising strategies in the treatment of oncology. Immune checkpoint inhibitors, as a type of immunotherapy, have no significant efficacy in the clinical treatment of patients with pMMR/MSS/MSI-L mCRC alone. Therefore, there is an urgent need to find combination therapies that can improve the response rate of immune checkpoint inhibitors. Oncolytic viruses are a new class of cancer drugs that, in addition to directly lysing tumor cells, can facilitate the action of immune checkpoint inhibitors by modulating the tumor microenvironment and transforming “cold” tumors into “hot” ones. The combination of oncolytic viruses and immune checkpoint inhibitors is currently being used in several primary and clinical studies to treat tumors with exciting results. The combination of genetically modified “armed” OV with ICIs is expected to be one of the treatment options for pMMR/MSS/MSI-L mCRC. In this paper, we will analyze the current status of oncolytic viruses and ICIs available for the treatment of CRC. The feasibility of OV in combination with ICI for CRC will be discussed in terms of the mechanism of action of OV in treating tumors.

show abstract

“…OVs can be delivered systemically or with direct intralesional injection into tumors (Zheng et al, 2019;Cook and Chauhan, 2020). The advantage of systemic administration include ease of administration and improved targeting of metastatic disease (Atasheva and Shayakhmetov, 2021). Prior studies in neuroendocrine cancer models with other OV therapies have demonstrated success with systemic infusions of OVs in combination with other immunomodulatory agents (Inoue et al, 2022).…”

Section: Seneca Valley Virus Studies In Mice and Humansmentioning

confidence: 99%

Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics

Corbett

Hallenbeck²,

Rychahou

et al. 2022

Front. Mol. Biosci.

View full text Add to dashboard Cite

Oncolytic viruses have made a significant inroad in cancer drug development. Numerous clinical trials are currently investigating oncolytic viruses both as single agents or in combination with various immunomodulators. Oncolytic viruses (OV) are an integral pillar of immuno-oncology and hold potential for not only delivering durable anti-tumor responses but also converting “cold” tumors to “hot” tumors. In this review we will discuss one such promising oncolytic virus called Seneca Valley Virus (SVV-001) and its therapeutic implications. SVV development has seen seismic evolution over the past decade and now boasts of being the only OV with a practically applicable biomarker for viral tropism. We discuss relevant preclinical and clinical data involving SVV and how bio-selecting for TEM8/ANTXR1, a negative tumor prognosticator can lead to first of its kind biomarker driven oncolytic viral cancer therapy.

show abstract

Oncolytic Viruses for Systemic Administration: Engineering a Whole Different Animal

Cited by 9 publications

References 15 publications

Oncolytic Virus‐Driven Biotherapies from Bench to Bedside

Oncolytic Virus‐Driven Biotherapies from Bench to Bedside

Oncolytic viruses combined with immune checkpoint therapy for colorectal cancer is a promising treatment option

Evolving role of seneca valley virus and its biomarker TEM8/ANTXR1 in cancer therapeutics

Contact Info

Product

Resources

About